ZOMDFOTCPharmaceutical PreparationsFiscal year ends December 31

Zomedica Corp.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$0.08−0.00 (-0.55%)

Close on Oct 19, 2026

Market cap: $77.40M
P/E (TTM): –
Dividend yield: –

Dividends

Zomedica has not reported a dividend

No dividend per share appears in Zomedica's annual filings since fiscal 2015.

Where these numbers come from

Parsed from the XBRL in Zomedica's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ZOMDF.

Revenue growth30.1% · median 22.6%

Gross margin65.4% · median 67.0%

Operating margin-56.3% · median -93.1%

Net margin-51.4% · median -76.0%

Company	Revenue	Growth
RMTI	$69.39M	-21.1%
AQST	$54.09M	+22.6%
ZOMDF	$36.88M	+30.1%
JAGX	$27.82M	+135.5%
ZYBT	–	–
BHST	–	–

Company

Next earnings (est.): Nov 3, 2026, during market hours
Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 141
Held by institutions: 0.0%
Auditor: GRANT THORNTON LLP
SEC CIK: 1684144

Advertisement
300 × 250